| 0.0003 0 (0%) | 05-06 15:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.07 | 1-year : | 0.09 |
| Resists | First : | 0.06 | Second : | 0.07 |
| Pivot price | 0.04 |
|||
| Supports | First : | 0.03 | Second : | 0.03 |
| MAs | MA(5) : | 0.04 |
MA(20) : | 0.04  |
| MA(100) : | 0.14 |
MA(250) : | 0.45 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.4 |
D(3) : | 18.3 |
| RSI | RSI(14): 44.1 |
|||
| 52-week | High : | 1.2 | Low : | 0.03 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VIVE ] has closed above bottom band by 36.9%. Bollinger Bands are 94.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 71 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.05 - 0.05 | 0.05 - 0.05 |
| Low: | 0.05 - 0.05 | 0.05 - 0.05 |
| Close: | 0.05 - 0.05 | 0.05 - 0.05 |
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Tue, 17 Jan 2023
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence - Yahoo Finance
Tue, 17 Jan 2023
Viveve Nosedives on Delisting Plans after Clinical Trial Failure - TipRanks.com - TipRanks
Tue, 17 Jan 2023
Viveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence Trial - Yahoo Finance
Tue, 17 Jan 2023
Viveve stock crashes ~60% as company decides to delist, explore sale after trial fails - Seeking Alpha
Tue, 17 Jan 2023
Why Is Viveve Medical (VIVE) Stock Down 69% Today? - InvestorPlace
Thu, 01 Dec 2022
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 11 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 374 (K) |
| Shares Short P.Month | 178 (K) |
| EPS | -3.22 |
| EPS Est Next Qtrly | -0.42 |
| EPS Est This Year | -1.95 |
| EPS Est Next Year | -1.39 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | -309.8 % |
| Return on Assets (ttm) | -62.2 % |
| Return on Equity (ttm) | -211 % |
| Qtrly Rev. Growth | 4.1 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.63 |
| EBITDA (p.s.) | -1.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | 0.43 |
| Price to Sales | 0.07 |
| Price to Cash Flow | -0.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2020-12-01 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|